Europe

Ovid Licenses European Rights to Lead Rare Disease Drug to Angelini Pharma
Ovid Licenses European Rights to Lead Rare Disease Drug to Angelini Pharma
Xconomy
Ovid Therapeutics
Angelman Syndrome
Angelini Pharma
Europe
clinical trials
Flag link:
Forbion Continues Funding Efforts, Raises $208M for More Investments
Forbion Continues Funding Efforts, Raises $208M for More Investments
BioSpace
venture capital
Forbion
Europe
Flag link:
Propeller gets green light to bundle its digital health tools with inhalers
Propeller gets green light to bundle its digital health tools with inhalers
MedCity News
Novartis
Propeller Health
Europe
digital health
inhalers
digital therapeutics
Flag link:
Spanish Covid-19 antibody study suggests herd immunity infeasible
Spanish Covid-19 antibody study suggests herd immunity infeasible
MedCity News
Spain
COVID-19
pandemic
herd immunity
Europe
antibody tests
Flag link:
J&J’s Ebola vaccine approved in EU
J&J’s Ebola vaccine approved in EU
Pharmaforum
Europe
JNJ
ebola virus
Janssen
vaccines
Bavarian Nordic
Flag link:
Takeda takes a $200M hit after Novartis is forced to yank its marketing application for Xiidra
Takeda takes a $200M hit after Novartis is forced to yank its marketing application for Xiidra
Endpoints
Takeda
Novartis
Xiidra
Europe
EMA
dry eye disease
Flag link:
Vertex : CHMP Grants Positive Opinion For KAFTRIO - KALYDECO In People Ages 12 And Older With CF
Vertex : CHMP Grants Positive Opinion For KAFTRIO - KALYDECO In People Ages 12 And Older With CF
Business Insider
Vertex Pharmaceuticals
Europe
EMA
CHMP
cystic fibrosis
Kalydeco
Kaftrio
Flag link:
Novartis strikes out with dry eye med Xiidra in Europe
Novartis strikes out with dry eye med Xiidra in Europe
Seeking Alpha
Novartis
dry eye disease
Europe
Xiidra
CHMP
Flag link:
COVID-19 drug remdesivir recommended for EU approval
COVID-19 drug remdesivir recommended for EU approval
Pharmaforum
Gilead
remdesivir
EMA
Europe
CHMP
COVID-19
Flag link:
BioGeneration Ventures €105M fund for early European biotechs
BioGeneration Ventures €105M fund for early European biotechs
Fierce Biotech
BioGeneration Ventures
Europe
biotech
venture capital
Flag link:
Biopharma industry urges MRA to mitigate risk of no-deal Brexit
Biopharma industry urges MRA to mitigate risk of no-deal Brexit
RAPS.org
UK
Europe
Brexit
MRA
EFPIA
Flag link:
Some Covid-19 trial sponsors never posted other study results in an EU database. Will they hide data again?
Some Covid-19 trial sponsors never posted other study results in an EU database. Will they hide data again?
Stat
COVID-19
Europe
clinical trials
clinical trial transparency
Flag link:
AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit
AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit
Pharmaceutical Business Review
AstraZeneca
vaccines
COVID-19
pandemic
Europe
University of Oxford
Flag link:
Surmodics' Regulatory Win Marks a Positive Shift in Paclitaxel Controversy
Surmodics' Regulatory Win Marks a Positive Shift in Paclitaxel Controversy
Medical Devices and Diagnostics Industry
SurModics
SurVeil
Europe
paclitaxel
devices
Flag link:
EU states back spending up to $2.7 billion upfront on COVID-19 vaccines
EU states back spending up to $2.7 billion upfront on COVID-19 vaccines
Reuters
Europe
COVID-19
vaccines
pandemic
Flag link:
Gilead files remdesivir for EU approval, with a verdict possible “in weeks”
Gilead files remdesivir for EU approval, with a verdict possible “in weeks”
Pharmaforum
EMA
Europe
Gilead Sciences
remdesivir
COVID-19
Flag link:
Europe mulls BARDA-style development contracts for COVID-19 vaccines: Bloomberg
Europe mulls BARDA-style development contracts for COVID-19 vaccines: Bloomberg
Fierce Pharma
Europe
vaccines
BARDA
COVID-19
Flag link:
EMA weighs COVID-19 data transparency, not ready to resume full clinical data publication
EMA weighs COVID-19 data transparency, not ready to resume full clinical data publication
RAPS.org
EMA
Europe
regulatory
clinical trial transparency
COVID-19
pandemic
Flag link:
EMA extends virtual-only meeting policy through August
EMA extends virtual-only meeting policy through August
Endpoints
EMA
Europe
FDA
COVID-19
pandemic
Flag link:
New Zolgensma 'inflection point' is here as Novartis snags EU nod for SMA gene therapy
New Zolgensma 'inflection point' is here as Novartis snags EU nod for SMA gene therapy
Fierce Pharma
Novartis
Zolgensma
SMA
spinal muscular atrophy
gene therapy
Europe
Flag link:

Pages